Super Bowl, Hims

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers Set To Run Impactful Super Bowl Ad
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss offerings in a way that will generate buzz.
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
Doctor weighs in on controversial weight loss drug commercial
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.
Hims & Hers Super Bowl Ad Controversy - Here's The Latest
Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants for profiting from America's obesity crisis. The company attracted flak from US Senators,
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
FiercePharma7h
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Hims & Hers Option Trade Offers $410 Return Or 17% Discount
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
FiercePharma1d
Pfizer wins 2025 Super Bowl with ad's 'likeability,' while Hims & Hers' spot takes engagement crown: analysts
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
HIMS stock soars to all-time high, reaching $46.11
In a remarkable display of market confidence, HIMS & Hers Health, Inc. (HIMS) stock has soared to an all-time high, with shares hitting a peak of $46.11. This milestone underscores the company's ...
What Is Hims Actually Selling?
The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...